Tenomix advances Lymphonator to near-commercial prototype and hospital validation
Western University reported that Tenomix had advanced its robotic ultrasound tissue-analysis system to a near-commercial prototype and begun validation work with Canadian and US hospitals.
Evidence notes
- The Lymphonator combines robotics, ultrasound imaging and AI to identify lymph nodes in resected cancer tissue.
- Tenomix progressed from its initial 2021 prototype to a near-commercial system and began testing with at least two Canadian hospitals.
- The company is targeting a Canadian commercial launch in 2027 while continuing hospital validation.